GenFleet Therapeutics (Shanghai) (HAM:Y3L) Retained Earnings: €-375.55 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:Y3L GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
19 GF Score
Price €2.92
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) Retained Earnings?

GenFleet Therapeutics (Shanghai) HAM:Y3L -2.80% 19 Retained Earnings is €-375.55 Mil as of Dec. 2025. GuruFocus rates HAM:Y3L with a GF Score™ of 19/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. GenFleet Therapeutics (Shanghai)'s retained earnings for the quarter that ended in Dec. 2025 was €-375.55 Mil.

GenFleet Therapeutics (Shanghai)'s quarterly retained earnings declined from Dec. 2024 (€-170.89 Mil) to Jun. 2025 (€-241.66 Mil) and declined from Jun. 2025 (€-241.66 Mil) to Dec. 2025 (€-375.55 Mil).

GenFleet Therapeutics (Shanghai)'s annual retained earnings increased from Dec. 2023 (€-174.60 Mil) to Dec. 2024 (€-170.89 Mil) but then declined from Dec. 2024 (€-170.89 Mil) to Dec. 2025 (€-375.55 Mil).


GenFleet Therapeutics (Shanghai)  (HAM:Y3L) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


GenFleet Therapeutics (Shanghai) Retained Earnings Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) Retained Earnings Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
Retained Earnings
-174.60 -170.89 -375.55

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Retained Earnings -174.60 0.00 -170.89 -241.66 -375.55
HAM:Y3L
19GF Score
GenFleet Therapeutics (Shanghai) Inc HAM:Y3L
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-375.55 Mil mean?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a Retained Earnings of €-375.55 Mil as of Dec. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on GenFleet Therapeutics (Shanghai) and its competitors.
Is GenFleet Therapeutics (Shanghai)'s Retained Earnings too high?
GenFleet Therapeutics (Shanghai)'s current Retained Earnings is €-375.55 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s Retained Earnings compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s Retained Earnings of €-375.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on GenFleet Therapeutics (Shanghai) and its competitors. GenFleet Therapeutics (Shanghai)'s current Retained Earnings is €-375.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HAM:Y3L) has a current Retained Earnings of €-375.55 Mil. The current Retained Earnings is €-375.55 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HAM:Y3L), the current Retained Earnings is €-375.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges 02595:Hong Kong
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
19GF Score

Get the complete analysis for HAM:Y3L

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.92
Price